ATE217345T1 - Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung - Google Patents

Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung

Info

Publication number
ATE217345T1
ATE217345T1 AT95930434T AT95930434T ATE217345T1 AT E217345 T1 ATE217345 T1 AT E217345T1 AT 95930434 T AT95930434 T AT 95930434T AT 95930434 T AT95930434 T AT 95930434T AT E217345 T1 ATE217345 T1 AT E217345T1
Authority
AT
Austria
Prior art keywords
diagnostic
proteins
virus
enclosure
therapeutic use
Prior art date
Application number
AT95930434T
Other languages
English (en)
Inventor
Geert Maertens
Fons Bosman
Martynoff Guy De
Marie-Ange Buyse
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8218662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE217345(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE217345T1 publication Critical patent/ATE217345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/913—Aspergillus
    • Y10S435/915—Aspergillus flavus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT95930434T 1994-07-29 1995-07-31 Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung ATE217345T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94870132 1994-07-29
PCT/EP1995/003031 WO1996004385A2 (en) 1994-07-29 1995-07-31 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Publications (1)

Publication Number Publication Date
ATE217345T1 true ATE217345T1 (de) 2002-05-15

Family

ID=8218662

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95930434T ATE217345T1 (de) 1994-07-29 1995-07-31 Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung

Country Status (13)

Country Link
US (7) US6150134A (de)
EP (3) EP1211315A1 (de)
JP (3) JPH09503396A (de)
AT (1) ATE217345T1 (de)
BR (1) BR9506059A (de)
CA (1) CA2172273A1 (de)
DE (2) DE69526636T3 (de)
DK (1) DK0721505T4 (de)
ES (1) ES2174957T5 (de)
HK (1) HK1049022A1 (de)
PT (1) PT721505E (de)
SG (1) SG71728A1 (de)
WO (1) WO1996004385A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174957T5 (es) 1994-07-29 2006-12-16 Innogenetics N.V. Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico.
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
CA2195312A1 (en) 1994-07-29 1996-02-15 Mark Selby Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
AU7471698A (en) 1997-05-06 1998-11-27 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
ATE482974T1 (de) 1997-11-06 2010-10-15 Innogenetics Nv Multimere peptide, die auf dem hepatitis c virus hüllprotein basieren, für diagnostische verwendung und für impfzwecke
WO1999024054A1 (en) * 1997-11-06 1999-05-20 Innogenetics N.V. Host derived proteins binding hcv: medical, diagnostic and purification use
EP0947525A1 (de) 1998-03-27 1999-10-06 Innogenetics N.V. Epitope in der viralen Hüllproteine und spezifische Antikörper gegen diese Epitope: Verwendung für die detektion von viralantigene im empfängergewebe
ES2230851T5 (es) * 1998-04-17 2009-06-25 N.V. Innogenetics S.A. Ensayos de inmunodiagnostico mejorados que usan agentes reductores.
NZ528952A (en) * 1998-06-24 2004-09-24 Innogenetics N Particles of HCV envelope proteins: use for vaccination
US7108855B2 (en) * 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU5285899A (en) 1998-07-21 2000-02-14 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7009044B1 (en) * 1999-06-04 2006-03-07 The United States Of America As Represented By The Department Of Health And Human Services HCV/BVDV chimeric genomes and uses thereof
CA2387666A1 (en) * 1999-10-27 2001-05-03 Innogenetics N.V. Redox reversible hcv proteins with native-like conformation
AU772617B2 (en) * 1999-11-19 2004-05-06 Csl Limited Vaccine compositions
US6740323B1 (en) * 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
JP2002030098A (ja) * 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7211414B2 (en) * 2000-12-01 2007-05-01 Visigen Biotechnologies, Inc. Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
BR0203518A (pt) * 2001-01-11 2002-12-17 Innogenetics Nv Proteìnas purificadas do envelope do vìrus de hepatite c para uso diagnóstico e terapêutico
ATE425187T1 (de) * 2001-01-12 2009-03-15 Molecules Of Man Ab Materialien und methoden zur behandlung von hepatitis c
US7048930B2 (en) * 2001-04-24 2006-05-23 Innogenetics N.V. Expression of core-glycosylated HCV envelope proteins in yeast
NZ530632A (en) * 2001-06-29 2007-04-27 Chiron Corp HCV E1E2 vaccine compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or CpG oligonucleotides
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN100395263C (zh) * 2003-01-31 2008-06-18 欧加农股份有限公司 缺氧条件下的蛋白质分离方法
US7524650B2 (en) * 2003-04-01 2009-04-28 Inserm Antibodies directed against hepatitis C virus E1E2 complex, compositions of HCV particles, and pharmaceutical compositions
US7788040B2 (en) * 2003-12-19 2010-08-31 Siemens Medical Solutions Usa, Inc. System for managing healthcare data including genomic and other patient specific information
JP4885476B2 (ja) * 2004-05-21 2012-02-29 株式会社日本触媒 タンパク質及び／又はペプチドの細胞内導入方法
EP1809773B1 (de) * 2004-10-18 2014-07-16 Globeimmune, Inc. Therapeutikum auf hefebasis gegen chronische hepatitis-c-infektion
US20060292647A1 (en) * 2004-12-03 2006-12-28 Green Lawrence R Reflex supplemental testing - A rapid, efficient and highly accurate method to identify subjects with an infection, disease or other condition
US20080124738A1 (en) * 2005-03-01 2008-05-29 Pritest, Inc Compositions and methods of testing for tuberculosis and mycobacterium infection
JP2008151505A (ja) * 2005-04-05 2008-07-03 Biomarker Science:Kk インターフェロン療法の有効性判定方法及び判定用キット
WO2008025067A1 (en) * 2006-08-30 2008-03-06 Hepgenics Pty Ltd Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
US20100286070A1 (en) * 2007-09-14 2010-11-11 Gert Verheyden Affinity tag
US20110091495A1 (en) * 2008-04-22 2011-04-21 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
WO2010111687A2 (en) 2009-03-27 2010-09-30 Academia Sinica Methods and compositions for immunization against virus
WO2011100508A2 (en) * 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2011147863A1 (en) 2010-05-25 2011-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
WO2012162137A1 (en) * 2011-05-20 2012-11-29 Emory University Hepatitis c virus particles, vaccines, compositions and methods related thereto
TW201346040A (zh) * 2012-03-30 2013-11-16 Tanaka Precious Metal Ind 流行性感冒ａ型病毒檢驗用套組
CA2886063C (en) 2012-09-27 2021-11-02 Msd Consumer Care, Inc. Foaming skincare formulations
US20170242010A1 (en) * 2014-02-11 2017-08-24 The Regents Of The University Of California Combo-Hepatitis Antigen Assays and Kits for Detection of Active Hepatitis Virus Infections
AU2017214685B2 (en) * 2016-02-05 2024-03-07 The Board Of Regents Of The University Of Texas System EGFL6 specific monoclonal antibodies and methods of their use
US11236153B2 (en) 2016-09-23 2022-02-01 Emory University Compositions and methods for identifying and sorting antigen-specific B cells
EP3519424A4 (de) * 2016-09-29 2020-06-03 Macfarlane Burnet Institute for Medical Research and Public Health Limited Assemblierte glykoproteine
CN109160942B (zh) * 2018-09-26 2021-06-29 广州市第八人民医院 Hcv包膜蛋白高度保守区域的肽段502-518及其用途
CN113125712B (zh) * 2019-12-31 2023-06-16 科美博阳诊断技术(上海)有限公司 一种丙型肝炎病毒抗体的均相化学发光检测试剂盒及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU48038B (sh) * 1987-11-18 1996-10-18 Chiron Corp. Postupak za dijagnostiku ne-a, ne-v hepatitisa
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
ATE118808T1 (de) * 1989-12-01 1995-03-15 Hoechst Ag Verwendung von komplexliganden für ionen in ferroelektrischen flüssigkristallmischungen.
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
EP0489153B1 (de) * 1990-06-29 1999-10-13 Chiron Corporation Liposomen enthaltende impfstoffzusammensetzungen
EP0554241A1 (de) * 1990-10-15 1993-08-11 LIPP, Robert Edmond Tragbare druckinfusionsvorrichtung für arzneimittellösungen
DE69131882T3 (de) * 1990-11-08 2007-05-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Asiloglycoproteine des hepatitis c-virus
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
DE69225960T2 (de) * 1991-01-31 1999-01-21 Abbott Laboratories, Abbott Park, Ill. Monoklonale antikörper gegen mögliche hcv-hüllregionen und methoden diese zu benutzen
FR2677372B1 (fr) * 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
AT397102B (de) * 1991-07-09 1994-02-25 Ahsen Uwe Von Dr Verwendung eines antibiotikums des typs 2-desoxystreptamin
IT1249684B (it) * 1991-07-19 1995-03-09 Sorin Biomedica Spa Epitopi della proteina env del virus dell'epatite c.
WO1993004088A1 (en) * 1991-08-21 1993-03-04 Abbott Laboratories Hepatitis c assay utilizing recombinant antigens to ns1
WO1993004888A1 (de) 1991-09-06 1993-03-18 Siemens Aktiengesellschaft Vorrichtung zur einhaltung einer vorgewählten fahrtrichtung eines fahrzeuges, insbesondere elektroautos, an steigungen
ATE228564T1 (de) * 1991-09-13 2002-12-15 Chiron Corp Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
DE69230917T3 (de) * 1991-09-16 2005-04-07 Abbott Laboratories, Abbott Park Verfahren zur detektion von hepatitis c
AU2683792A (en) * 1991-09-16 1993-04-27 Genelabs Technologies, Inc. Peptide based hepatitis c virus immunoassays
JP3158177B2 (ja) * 1991-10-08 2001-04-23 国立感染症研究所長 Ｃ型肝炎診断薬
ES2210235T3 (es) * 1992-01-31 2004-07-01 Abbott Laboratories Sistemas de expresion de mamiferos para proteinas de hcv.
JP3443809B2 (ja) * 1992-03-06 2003-09-08 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 免疫学的に重要なエピトープに相当するペプチドの決定方法、及び免疫学的に重要なエピトープに相当するビオチニル化ペプチド又は抗体の決定のための方法におけるその利用、その調製方法及びそれを含む組成物
US5866139A (en) * 1992-06-04 1999-02-02 Institut Pasteur Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications
JPH05344899A (ja) 1992-06-11 1993-12-27 Kokuritsu Yobou Eisei Kenkyusho Ｃ型肝炎ウイルス外被タンパク質の産生法
UA39944C2 (uk) * 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
ES2174957T5 (es) 1994-07-29 2006-12-16 Innogenetics N.V. Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico.
PT773957E (pt) * 1994-07-29 2005-11-30 Chiron Corp Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
EP0947525A1 (de) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitope in der viralen Hüllproteine und spezifische Antikörper gegen diese Epitope: Verwendung für die detektion von viralantigene im empfängergewebe

Also Published As

Publication number Publication date
PT721505E (pt) 2002-10-31
HK1049022A1 (zh) 2003-04-25
WO1996004385A2 (en) 1996-02-15
US20080138894A1 (en) 2008-06-12
BR9506059A (pt) 1997-10-28
WO1996004385A3 (en) 1996-03-07
US6245503B1 (en) 2001-06-12
EP1211315A1 (de) 2002-06-05
SG71728A1 (en) 2000-04-18
CA2172273A1 (en) 1996-02-15
US20020182706A1 (en) 2002-12-05
US7026457B2 (en) 2006-04-11
JPH09503396A (ja) 1997-04-08
JP2004222729A (ja) 2004-08-12
EP0721505B1 (de) 2002-05-08
EP0721505A1 (de) 1996-07-17
US6150134A (en) 2000-11-21
DK0721505T4 (da) 2006-08-14
DK0721505T3 (da) 2002-08-19
ES2174957T3 (es) 2002-11-16
ES2174957T5 (es) 2006-12-16
US20070128721A1 (en) 2007-06-07
DE69526636D1 (de) 2002-06-13
DE69526636T3 (de) 2006-11-23
JP3892443B2 (ja) 2007-03-14
JP4105203B2 (ja) 2008-06-25
DE69526636T2 (de) 2002-12-12
DE69526636T4 (de) 2003-06-26
EP0721505B2 (de) 2006-05-10
JP2007105038A (ja) 2007-04-26
EP1845108A3 (de) 2007-10-24
US6890737B1 (en) 2005-05-10
US20030036110A1 (en) 2003-02-20
EP1845108A2 (de) 2007-10-17

Similar Documents

Publication Publication Date Title
ATE217345T1 (de) Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung
EP0591914A3 (en) Retrovirus of the hiv-group and its application
DE59109221D1 (de) HCV-spezifische Peptide, Mittel dazu und ihre Verwendung
ES2035920T3 (es) Aerolizacion de agente proteico terapeutico.
DE3886060D1 (de) Vorläuferprotein des APC-Polypeptids, dafür codierende DNA und diagnostische Verwendung der DNA und des Proteins.
DK0992580T3 (da) Epitoper på human T-celler, som er immundominante for hepatitis C-virus
DK0759067T3 (da) Transformerende vækstfaktor alfa-H1
DE59209921D1 (de) Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
DE69333673D1 (de) Epitope von Stress Proteinen
ATE310817T1 (de) Verfahren und zusammensetzungen zur kontrolle der übersetzung der hcv-proteine
DK0871474T4 (da) Fremstilling af human insulin
PT804562E (pt) Factor 2 de crescimento de tecido conjuntivo
MXPA04005891A (es) Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico.
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DK0937153T3 (da) Humane monoklonale antistoffer, der er specifikke for hepatitis C-virus (HCV) E2 antigen
ES2062759T3 (es) Procedimiento de purificacion de polipeptidos recombinantes.
IT1264332B1 (it) Composizione per il trattamento di infezioni e malattie causate dal virus dell'epatite b (hpv)
DE69832299D1 (de) Einkettigen polypeptiden enthalten troponin i und troponin c
WO2002055548A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
ATE176672T1 (de) Hcv-peptide und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0721505

Country of ref document: EP

REN Ceased due to non-payment of the annual fee